A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

计划入组 170 人 · 首次发布于 2024 年 7 月 15 日

A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

计划入组 675 人 · 首次发布于 2024 年 11 月 26 日

Evaluation of Behavioral Health-Virtual Patient Navigation Team (BH-VPN)

计划入组 637 人 · 首次发布于 2017 年 7 月 2 日

BH-02

BH-009

BH-04

Biglari Holdings

United States

常州吾合生物医药有限责任公司

Eastern Cooperative Oncology Group

United States

HMNC Brain Health Secures $50 Million Series B Financing and European Partnership with MEDICE for Precision Psychiatry Pipeline

HMNC Brain Health Completes Patient Randomization in Phase 2b Trial of BH-200 for Major Depressive Disorder

HMNC Brain Health's BH-200 Shows Promising Results in Phase 2 Depression Trial with Genetic Selection Tool